Acceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a
webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m.
EST to discuss its fourth quarter and full year 2018 operating and
financial results.

The webcast will be accessible under “Events & Presentations” in the
Investors/Media page of the company’s website at www.acceleronpharma.com.
Individuals can participate in the conference call by dialing
877-312-5848 (domestic) or 253-237-1155 (international) and refer to the
“Acceleron Fourth Quarter and Full Year 2018 Earnings Call.”

The archived webcast will be available for replay on the Acceleron
website approximately two hours after the event.

About Acceleron

Acceleron is a clinical-stage biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to treat
serious and rare diseases. The Company’s leadership in the understanding
of TGF-beta biology and protein engineering generates innovative
compounds that engage the body’s ability to regulate cellular growth and
repair.

Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary
arterial hypertension.

For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma
and LinkedIn.

Contacts

Acceleron Pharma Inc.
Investors:
Todd James, IRC, (617)
649-9393
Vice President, Investor Relations and Corporate
Communications
or
Media:
Matt Fearer, (617) 301-9557
Director,
Corporate Communications

error: Content is protected !!